Lexeo Therapeutics, Inc. Common Stock (LXEO) — Financial Flexibility Index
Lexeo Therapeutics, Inc. Common Stock (LXEO) has a Financial Flexibility Index of -1.12x as of March 2026. Free cash flow of $-21.11 Million (operating CF $-21.14 Million minus capex $35.00K) represents -1% of total liabilities ($18.86 Million). Also explore LXEO net assets growth trend to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lexeo Therapeutics, Inc. Common Stock Financial Flexibility Index (2020–2025)
Historical Financial Flexibility Index trend for Lexeo Therapeutics, Inc. Common Stock across 6 annual periods. Check Lexeo Therapeutics, Inc. Common Stock (LXEO) strategic investment index to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Lexeo Therapeutics, Inc. Common Stock (2020–2025)
Year-by-year free cash flow to debt coverage for Lexeo Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see Lexeo Therapeutics, Inc. Common Stock stock valuation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -4.46x | $-98.16 Million | $-98.56 Million | $22.02 Million | ▼ -66.3% |
| 2024 | -2.68x | $-80.67 Million | $-81.15 Million | $30.10 Million | ▼ -18.7% |
| 2023 | -2.26x | $-59.33 Million | $-59.50 Million | $26.27 Million | ▼ -783.9% |
| 2022 | -0.26x | $-53.66 Million | $-54.56 Million | $210.03 Million | ▼ -11.8% |
| 2021 | -0.23x | $-43.99 Million | $-44.18 Million | $192.46 Million | ▼ -154.9% |
| 2020 | -0.09x | $-3.13 Million | $-3.13 Million | $34.95 Million | — |